Recent research has also explored blocking the CCL2/CCR2 signaling axis, responsible for monocyte recruitment and M2 differentiation, as a promising strategy to reduce TAM infiltration in the TME and enhance anti-tumor immune responses. This evidence concerns the gene CCR2 and neoplasm.